ESG

A new partnership brings advanced, non-invasive Alzheimer's blood tests to community centers, aiming for mass early detection and reshaping diagnostics.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

Lorissa's Organic Snacks expands with certified allergen-free options, but a look at the market reveals a competitive race for consumer trust and safety.

With its sixth deal of 2026, WhiteHawk expands its footprint in the Haynesville Shale, tying its fortunes to the booming but controversial U.S. LNG market.

The infant nutrition giant is entering Canada's booming organic market, betting on brand trust to compete in an increasingly crowded and conscious space.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

Total Joint Orthopedics surpasses 50,000 implants, signaling a major shift as surgeries move from hospitals to efficient, cost-effective surgery centers.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

Riding high on U.S. success, GEEK BAR returns to Europe with a reusable vape, a strategic pivot as the continent wages war on disposable products.

McFarlane Lake Mining's latest drill results reveal a massive 95.4-meter gold intersection, signaling a major expansion of its Juby gold project.

Private equity giant Warburg Pincus invests up to $1 billion in Global Eggs, fueling a rapid consolidation of the world's protein supply.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

The 135-year-old industry pioneer swept the 2026 TRSA awards, showcasing excellence in service, leadership, and sustainability across three continents.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

With over 90% investor participation, Gran Tierra Energy extends its debt maturity to 2031, securing crucial financial flexibility in a volatile market.

Nova Minerals confirms a major gold-copper system at its Estelle Project, with high-grade samples boosting US critical mineral prospects and exciting investors.